Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models.
The antithrombotic effect of MCI-9042, (+-)-2-(dimethyl-amino)-1-((o-(m- methoxyphenethyl)phenoxyl]methyl]ethyl hydrogen succinate hydrochloride was investigated in three different experimental thrombosis models in animals. Simultaneous injection of serotonin and collagen into the tail vein in mice induced acute pulmonary thromboembolic death. MCI-9042 reduced the mortality in a dose dependent manner and its ED50 value was 1.9 mg/kg po. Ticlopidine (TCP) which is a positive reference compound as an antithrombotic drug reduced the mortality at doses of 10 mg/kg po and above. Cyproheptadine (CPH) and ketanserin (KTS) which are S2-serotonergic antagonists were also effective on the reduction of mortality. In mesenteric arterial thrombosis induced by electric stimulation in mice, MCI-9042 prolonged the occlusion time resulted from platelet thrombus formation (PD50: 23 mg/kg po). CPH and KTS prolonged the occlusion time as potent as MCI-9042, but TCP prolonged the occlusion time only at the high doses of 100 mg/kg po and above. In experimental arterial thrombosis which generated in implanted polyethylene tubing, MCI-9042 reduced the incidence of thrombus formation in the tubing and its ED50 value was 18 mg/kg po. TCP was also effective in this model with an ED50 of 170 mg/kg po. The present results lead to the consideration that serotonin plays a more important role in thrombus formation than that conjectured formerly, and suggest that MCI-9042 becomes a new kind of antithrombotic drug with S2-serotonergic receptor antagonism.
Hara
H
H
Pharmaceuticals Laboratory, Mitsubishi Kasei Corporation, Yokohama, Japan.
Kitajima
A
A
Shimada
H
H
Tamao
Y
Y
D000818:Animals; D004558:Electric Stimulation; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D008297:Male; D008638:Mesenteric Arteries; D051379:Mice; D008815:Mice, Inbred Strains; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011095:Polyethylenes; D019736:Prostheses and Implants; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000188:drug therapy*; D013386:Succinates / Q000627:therapeutic use*; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011095:Polyethylenes; D013386:Succinates; C064294:sarpogrelate